TY - JOUR
T1 - Phenelzine vs atenolol in social phobia - A placebo-controlled comparison
AU - Liebowitz, Michael R.
AU - Schneier, Frank
AU - Campeas, Raphael
AU - Hollander, Eric
AU - Hatterer, Julie
AU - Fyer, Abby
AU - Gorman, Jack
AU - Papp, Laslo
AU - Davies, Sharon
AU - Gully, Robert
AU - Klein, Donald F.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1992
Y1 - 1992
N2 - Seventy-four patients who met DSM-III criteria for social phobia completed 8 weeks of double-blind, randomly assigned treatment with the monoamine oxidase inhibitor phenelzine sulfate, the cardioselective β-adrenergic blocker atenolol, or placebo. The overall response rates were 64% for phenelzine, 30% for atenolol, and 23% for placebo. Phenelzine was widely superior to both atenolol and placebo on independent rater analyses and, to a lesser extent, on self-report, with no significant differences between atenolol and placebo. At the end of 16 weeks, phenelzine was still significantly superior to placebo, while atenolol showed an intermediate response that did not differ significantly from either of the other treatments. Patients with generalized social phobia constituted 76% of the sample, and they were preferentially responsive to phenelzine. The small size of the discrete social phobic sample precluded separate outcome analyses for this subtype. Overall, the findings support the responsivity of social phobia to monoamine oxidase inhibitors.
AB - Seventy-four patients who met DSM-III criteria for social phobia completed 8 weeks of double-blind, randomly assigned treatment with the monoamine oxidase inhibitor phenelzine sulfate, the cardioselective β-adrenergic blocker atenolol, or placebo. The overall response rates were 64% for phenelzine, 30% for atenolol, and 23% for placebo. Phenelzine was widely superior to both atenolol and placebo on independent rater analyses and, to a lesser extent, on self-report, with no significant differences between atenolol and placebo. At the end of 16 weeks, phenelzine was still significantly superior to placebo, while atenolol showed an intermediate response that did not differ significantly from either of the other treatments. Patients with generalized social phobia constituted 76% of the sample, and they were preferentially responsive to phenelzine. The small size of the discrete social phobic sample precluded separate outcome analyses for this subtype. Overall, the findings support the responsivity of social phobia to monoamine oxidase inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=0026516493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026516493&partnerID=8YFLogxK
U2 - 10.1001/archpsyc.49.4.290
DO - 10.1001/archpsyc.49.4.290
M3 - Article
C2 - 1558463
AN - SCOPUS:0026516493
SN - 0003-990X
VL - 49
SP - 290
EP - 300
JO - Archives of General Psychiatry
JF - Archives of General Psychiatry
IS - 4
ER -